

R H I N O M E D

RHINOMED RECEIVES \$570k R&D TAX INCENTIVE TO SUPPORT BREATHEASSIST™ PLATFORM TECHNOLOGY DEVELOPMENT

Melbourne, Australia. December 22, 2014.

Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has received a Research and Development tax refund of \$570,337.

Rhinomed Limited intends to apply these funds to continue the development and commercialization of its BreatheAssist platform technology and for working capital purposes.

Media Enquiries

Michael Johnson, CEO & Managing Director

+61 (0) 3 8416 0900

mjohnson@rhinomed.com.au

Follow us on twitter  @rhinomedceo

About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a medical technology firm with a focus on nasal, respiratory and breathing management technologies. The company is commercialising its BreatheAssist platform technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to: www.rhinomed.com.au

You can purchase a Turbine by visiting www.theturbine.com and a Mute at www.mutesnoring.com